BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25071071)

  • 1. Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.
    Kim MJ; Lee WY; Choe YH
    Gut Liver; 2015 May; 9(3):370-80. PubMed ID: 25071071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-regulation of innate and adaptive immunity: a new perspective for the pathogenesis of inflammatory bowel disease.
    Oh DY; Koh SJ
    Gut Liver; 2015 May; 9(3):263-4. PubMed ID: 25918258
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
    Ricciardelli I; Lindley KJ; Londei M; Quaratino S
    Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
    Li Z; Arijs I; De Hertogh G; Vermeire S; Noman M; Bullens D; Coorevits L; Sagaert X; Schuit F; Rutgeerts P; Ceuppens JL; Van Assche G
    Inflamm Bowel Dis; 2010 Aug; 16(8):1299-310. PubMed ID: 20196149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ CD25+ FOXP3+ T cell frequency in the peripheral blood is a biomarker that distinguishes intestinal tuberculosis from Crohn's disease.
    Tiwari V; Kedia S; Garg SK; Rampal R; Mouli VP; Purwar A; Mitra DK; Das P; Dattagupta S; Makharia G; Acharya SK; Ahuja V
    PLoS One; 2018; 13(2):e0193433. PubMed ID: 29489879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
    Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
    J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-17 immunity in pediatric Crohn disease and ulcerative colitis.
    Hölttä V; Klemetti P; Salo HM; Koivusalo A; Pakarinen M; Westerholm-Ormio M; Kolho KL; Vaarala O
    J Pediatr Gastroenterol Nutr; 2013 Sep; 57(3):287-92. PubMed ID: 23974060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
    Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
    Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressive and Gut-Reparative Functions of Human Type 1 T Regulatory Cells.
    Cook L; Stahl M; Han X; Nazli A; MacDonald KN; Wong MQ; Tsai K; Dizzell S; Jacobson K; Bressler B; Kaushic C; Vallance BA; Steiner TS; Levings MK
    Gastroenterology; 2019 Dec; 157(6):1584-1598. PubMed ID: 31513797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulated upregulation of T-cell immunoglobulin and mucin domain-3 on mucosal T helper 1 cells in patients with Crohn's disease.
    Morimoto K; Hosomi S; Yamagami H; Watanabe K; Kamata N; Sogawa M; Machida H; Okazaki H; Tanigawa T; Nagahara H; Noda E; Tominaga K; Watanabe T; Fujiwara Y; Maeda K; Hirakawa K; Arakawa T
    Scand J Gastroenterol; 2011 Jun; 46(6):701-9. PubMed ID: 21463244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease.
    Kelsen J; Agnholt J; Hoffmann HJ; Rømer JL; Hvas CL; Dahlerup JF
    Clin Exp Immunol; 2005 Sep; 141(3):549-57. PubMed ID: 16045746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
    Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase of regulatory T cells in ileal mucosa of untreated pediatric Crohn's disease patients.
    Reikvam DH; Perminow G; Lyckander LG; Gran JM; Brandtzaeg P; Vatn M; Carlsen HS
    Scand J Gastroenterol; 2011 May; 46(5):550-60. PubMed ID: 21281255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
    Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease.
    Di Sabatino A; Biancheri P; Piconese S; Rosado MM; Ardizzone S; Rovedatti L; Ubezio C; Massari A; Sampietro GM; Foschi D; Porro GB; Colombo MP; Carsetti R; MacDonald TT; Corazza GR
    Inflamm Bowel Dis; 2010 Nov; 16(11):1891-7. PubMed ID: 20848485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease.
    Wang Y; Liu XP; Zhao ZB; Chen JH; Yu CG
    J Dig Dis; 2011 Aug; 12(4):286-94. PubMed ID: 21791023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease.
    Wehkamp J; Fellermann K; Herrlinger KR; Baxmann S; Schmidt K; Schwind B; Duchrow M; Wohlschläger C; Feller AC; Stange EF
    Eur J Gastroenterol Hepatol; 2002 Jul; 14(7):745-52. PubMed ID: 12169983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T2 enhances in situ level of Foxp3+ regulatory cells and modulates inflammatory cytokines in Crohn's disease.
    Li G; Ren J; Wang G; Gu G; Hu D; Ren H; Hong Z; Wu X; Liu S; Li J
    Int Immunopharmacol; 2014 Feb; 18(2):244-8. PubMed ID: 24369313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy.
    Li Z; Vermeire S; Bullens D; Ferrante M; Van Steen K; Noman M; Rutgeerts P; Ceuppens JL; Van Assche G
    Inflamm Bowel Dis; 2015 Oct; 21(10):2418-28. PubMed ID: 26308438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
    Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
    Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.